Compare · LNTH vs TKNO
LNTH vs TKNO
Side-by-side comparison of Lantheus Holdings Inc. (LNTH) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNTH and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH is the larger of the two at $6.68B, about 13.6x TKNO ($491.3M).
- LNTH has been more active in the news (13 items in the past 4 weeks vs 3 for TKNO).
- LNTH has more recent analyst coverage (18 ratings vs 10 for TKNO).
- Company
- Lantheus Holdings Inc.
- Alpha Teknova Inc.
- Price
- -
- -
- Market cap
- $6.68B
- $491.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 13
- 3
- Recent ratings
- 18
- 10
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Latest LNTH
- Executive Chair and CEO Mary Anne Heino covered exercise/tax liability with 6,206 shares, decreasing direct ownership by 2% to 315,691 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Lantheus Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
- Amendment: SEC Form SCHEDULE 13D/A filed by Lantheus Holdings Inc.
- PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- SEC Form 10-Q filed by Lantheus Holdings Inc.
- Lantheus Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest TKNO
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Third Quarter 2026 Financial Results
- Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 8-K filed by Alpha Teknova Inc.
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Pricing of $40 Million Public Offering of Common Stock
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Proposed Public Offering of Common Stock
- Teknova Announces Preliminary Third Quarter Financial Results